Award

Ask AI about this notice

Summarise, research or assess it with AI

View Markdown

Share this notice

Send this contract to a colleague

Onasemnogene Abeparvovec Intravenous (Zolgensma(r)) Service & Onasemnogene Abeparvovec Intrathecal (OAV101 IT) Service

NHS England

This public procurement record has 2 releases in its history.

Award

22 Sep 2026 at 16:39

Award Notice
Tender

04 Jun 2026 at 16:37

Tender Notice
Summary of the contracting process

NHS England procured specialist health services for people with spinal muscular atrophy across the UK. The requirement covers one-time intravenous onasemnogene abeparvovec (Zolgensma) gene-replacement treatment for babies aged 12 months and under, and proposed one-time intrathecal OAV101 IT treatment for patients aged two and over, subject to NICE recommendations. The service uses gene replacement to restore production of survival motor neuron protein. Zolgensma and OAV101 IT are intended for distinct patient cohorts, with OAV101 IT covering paediatric and adult patients. Delivery is through NHS providers serving the population commissioned by NHS England. Selected providers include NHS foundation trusts and hospitals in Bristol, London, Oxford, Newcastle, Southampton, Sheffield, Leeds, Manchester, Liverpool, Salford, Stoke-on-Trent and other UK locations. The procurement is for health services, CPV 85100000.

The procurement has reached the awarded stage, with active awards and signed active contracts dated 24 August 2026. NHS England used an open procedure, with nine bids recorded for the first award group and 11 for the subsequent award groups. The estimated procurement value is £26,136,000. Lot values were £8,527,000 for Zolgensma alone, £9,326,000 for the combined paediatric and Zolgensma provision, and £8,283,000 for adult OAV101 IT provision. Contract durations are 1,800 days, with options to extend by up to two years. Individual contract values are £1,036,000, £776,000 or £753,000, depending on the award. Awards were made to 31 award positions across 16 NHS providers, including Northern Care Alliance, University Hospitals Bristol and Weston, Sheffield Teaching Hospitals, Oxford University Hospitals and others. The standalone Lot 1, paediatric Lot 2 and adult Lot 3 configurations were cancelled; the active awards reflect alternative combinations. Evaluation weighted quality at 90% and social value at 10%, with price weighted at 0%.

This requirement is relevant to established specialist NHS, hospital and clinical providers able to deliver advanced gene-replacement treatment for spinal muscular atrophy within NHS pathways. The awarded supplier profile shows that large NHS foundation trusts and specialist children’s and teaching hospitals were considered credible, including providers with paediatric, adult and highly specialised neurology or gene-therapy capability. A future competitor would need to demonstrate that it can meet all mandatory requirements and the minimum quality threshold, rather than relying on price differentiation. Strong clinical governance, capacity to identify and treat eligible patients, safe intravenous and intrathecal treatment pathways, and the ability to serve a defined NHS population would be central. The evaluation also placed substantial emphasis on quality and included a social-value requirement, so providers would need evidence of service quality, organisational capability and wider NHS value.

How relevant is this notice?

Notice Information

Notice Title

Onasemnogene Abeparvovec Intravenous (Zolgensma(r)) Service & Onasemnogene Abeparvovec Intrathecal (OAV101 IT) Service

Notice Description

Intention to award the Onasemnogene Abeparvovec Intravenous (Zolgensma(r)) Service & Onasemnogene Abeparvovec Intrathecal (OAV101 IT) Service. <br/><br/>This is a a one-time, in vivo gene replacement therapy, for use in babies aged 12 months and under, that utilises an adeno-associated virus serotype 9 (AAV9) vector, modified to contain a functional copy of the human SMN1 gene. It is administered intravenously, allowing the vector to deliver the gene into motor neurones and peripheral tissues, enabling the sustained expression of survival motor neuron (SMN) protein, which is deficient or mutated in individuals with SMA.<br/><br/>Onasemnogene abeparvovec intrathecal (OAV101 IT) is a one-time in vivo gene replacement therapy for patients with SMA, proposed to treat individuals with SMA aged 2 years and over. This intrathecal injection will be used to treat a distinct cohort of SMA patients to Zolgensma. It will be assessed via NICE's technology appraisal programme, with an expected final guidance publication date in late 2026.<br/><br/>Procurement was carried out in Lots for the services as detailed above. Contract values are estimated and will be dependent on number of patients actually treated at each awarded provider.

Lot Information

Lot 1

Lot 1: Zolgensma only (if no positive NICE recommendation for OAV101 IT)

Options: Contract period for 3 years with the option to extend up to 2 additional years

Renewal: Commissioners may decide to to renew the contract at the end of its term

Lot 3

Lot 3: Positive NICE recommendation for OAV101 IT for adult patients (either standalone or in combination with Lots 1 and 2) Additional information: Lot 3: Positive NICE recommendation for OAV101 IT for adult patients (either standalone or in combination with Lots 1 and 2)

Options: The commissioners have the option to extend for a further 2 years

Renewal: Commissioners may decide to to renew the contract at the end of its term

Lots 3

Lot 3: Positive NICE recommendation for OAV101 IT for adult patients (either standalone or in combination with Lots 1 and 2)

Options: Contract period for 3 years with the option to extend up to a further 2 years

Renewal: Commissioners may decide to to renew the contract at the end of its term

Lot 1

Lot 1: Zolgensma only (if no positive NICE recommendation for OAV101 IT)

Options: Commissioners have the option to extend the contract for a further two years

Lot 2

Lot 2: Positive recommendation for OAV101 IT for paediatric patients (in combination with Lot 1 for Zolgensma)

Options: Commissioners have the option to extend the contract for a further two years

Notice Details

Publication & Lifecycle

Open Contracting ID
ocds-h6vhtk-06ae08
Publication Source
Find A Tender Service
Latest Notice
https://www.find-tender.service.gov.uk/Notice/089823-2026
Current Stage
Award
All Stages
Tender, Award

Procurement Classification

Notice Type
Award Notice
Procurement Type
Standard
Procurement Category
Services
Procurement Method
Open
Procurement Method Details
Open procedure
Tender Suitability
Not specified
Awardee Scale
Large

Common Procurement Vocabulary (CPV)

CPV Divisions

85 - Health and social work services

CPV Codes

85100000 - Health services

Notice Value(s)

Tender Value
£26,136,000 £10M-£100M
Lots Value
£26,136,000 £10M-£100M
Awards Value
Not specified
Contracts Value
£2,565,000 £1M-£10M

Notice Dates

Publication Date
22 Sep 20261 months ago
Submission Deadline
8 Jul 2026Expired
Future Notice Date
Not specified
Award Date
Not specified
Contract Period
Not specified - Not specified
Recurrence
Not specified

Notice Status

Tender Status
Complete
Lots Status
Active, Cancelled
Awards Status
Active
Contracts Status
Active

Buyer & Supplier

Contracting Authority (Buyer)

Main Buyer
NHS England
Contact Name
Available with D3 Tenders Premium →
Contact Email
Available with D3 Tenders Premium →
Contact Phone
Available with D3 Tenders Premium →

Buyer Location

Locality
LONDON
Postcode
SE1 8UG
Postcode Area
South East London
Country
England
Major Region (ITL 1)
TLI London
Basic Region (ITL 2)
TLI4 Inner London - East
Small Region (ITL 3)
TLI45 Lambeth
Delivery Location
Not specified
Local Authority
Lambeth
Electoral Ward
Waterloo & South Bank
Westminster Constituency
Vauxhall and Camberwell Green

Supplier Information

Number of Suppliers
16
Supplier Names

Northern Care Alliance NHS Foundation Trust

University Hospitals Bristol and Weston NHS Foundation Trust

Sheffield Teaching Hospitals NHS Foundation Trust

Oxford University Hospitals NHS FT

The Newcastle upon Tyne Hospitals NHS Foundation Trust

University Hospitals Southampton

University College London Hospitals NHS Foundation Trust

St George's University Hospitals NHS Foundation Trust

KING'S COLLEGE HOSPITAL NHS FT

Great Ormond Street Hospital

Guy's and St Thomas' NHS Foundation Trust

University Hospitals of North Staffordshire NHS Trust

Sheffield Children's NHS Foundation Trust

Leeds Teaching Hopsital NHS Foundation Trust

North Manchester General Hospital

AlderHey Children's NHS FT

Further Information

Open Contracting Data Standard (OCDS)

View full OCDS Record for this contracting process

JSON Markdown

The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.

Loading OCDS record...